Netherlands-based oncology drugs developer Modra Pharmaceuticals has started patient enrolment in a Phase II clinical trial of modraDoc006/r to treat patients with metastatic castration-resistant prostate cancer.

ModraDoc006/r is an oral formulation of docetaxel (ModraDoc006) given along with boosting-agent ritonavir to improve bioavailability of the chemotherapy.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Ritonavir is an inhibitor of the drug efflux transporter protein P-glycoprotein (P-gp) and the liver enzyme cytochrome P450 3A4 (CYP3A4).

The systemic bioavailability of docetaxel is enhanced by ritonavir through inhibition of metabolism.

The multi-centre Phase II trial is designed to evaluate the safety, feasibility and pharmacokinetic profile of the formulation in 20 chemotherapy naïve patients indicated with intravenous (IV) docetaxel.

"With the promising results we have seen in our Phase I studies and given the nature of our approach, we are highly confident that we can advance this compound quickly with the aim to initiate a pivotal programme by early 2018."

Modra Pharmaceuticals CEO Eric van der Putten said: “Modra Pharmaceuticals aims to apply its oral formulation technology in oncology, with an initial focus on taxane-based chemotherapy, to offer patients a better quality-of-life through a simpler and more effective route of administration.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“With the promising results we have seen in our Phase I studies and given the nature of our approach, we are highly confident that we can advance this compound quickly with the aim to initiate a pivotal programme by early 2018.”

The dose-escalation trial will further establish a feasible dosing regimen of the formulation and the maximum tolerated dose that is safe to be given in a bi-daily weekly schedule without intervals.

The trial’s secondary outcome is the measure of pharmacodynamics of modraDoc006/r.

The firm aims to offer clinicians with multiple options for prescribing combinatorial treatments of cancer regimens.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact